Given a list of 40 drugmakers, the respondents rated ViiV most highly in terms of corporate reputation, followed by ...

Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the ...

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Just a few weeks after Omnicom announced in early December its plans to acquire fello | Craig Romanok, chief marketing ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

On Nov. 9, 2020, Pfizer and partner BioNTech announced that the vaccine had met the first effectiveness bar in a key study.